CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused...
Biosplice expands its clinical candidate, cirtuvivint, as standalone treatment and combination therapy in patients with AML and MDS, representing next...
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard...
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo...
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a...
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination...
HACKENSACK, NJ / ACCESSWIRE / September 11, 2024 / Royal Wound-X, a division of Royal Biologics dedicated to advancing wound...
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...
Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11,...
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare productsATLANTA, Sept....
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
FORT LAUDERDALE, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII),...
Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to...
Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation...
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of...
BOSTON, Sept. 10, 2024 /PRNewswire/ -- AG Mednet, the pioneering force in clinical trial process management, continues to experience rapid...
Expanding Impact to Connect Healthcare Companies and Their Most Important Audiences PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Health Union, the...
CLEVELAND, Sept. 10, 2024 /PRNewswire/ -- September 4th, 2024. GenomOncology, a leading provider of precision medicine software, and Precipio, a...
SAN ANTONIO, Sept. 10, 2024 /PRNewswire/ -- RealTime eClinical Solutions, a leader in clinical trial technology, proudly announces its continued...